{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:49Z","timestamp":1787028529482,"version":"build-2736575974"},"reference-count":56,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T00:00:00Z","timestamp":1705190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Risk-reducing bilateral salpingo-oophorectomy (RRSO) is recommended for breast cancer gene 1 (BRCA1) and 2 (BRCA2) mutation carriers. A major consequence of RRSO is surgical menopause associated with severe menopausal symptoms, mostly genitourinary complaints. Due to the inherent breast cancer risk, estrogen-based therapies are generally avoided in these patients. So far, the non-hormonal approaches available are not efficient to successfully treat the disabling vaginal atrophy-related symptoms. In regenerative medicine, mesenchymal stem cells (MSC) are the most frequently used cell type due to their remarkable and regenerative characteristics. Therapies based on MSC have revealed positive outcomes regarding symptoms and signs associated with vaginal atrophy by promoting angiogenesis, vaginal restoration, and the proliferation of vaginal mucosa cells. Menstrual blood-derived stem cells (MenSC) are a novel source of MSC, with promising therapeutic potential directly linked to their high proliferative rates; low immunogenicity; non-invasive, easy, and periodic acquisition; and almost no associated ethical issues. In this review, we update the current knowledge and research regarding the potential value of previously preserved MenSC in the therapy of vaginal atrophy among BRCA mutation carriers subjected to RRSO.<\/jats:p>","DOI":"10.3390\/ijms25021025","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:03:26Z","timestamp":1705291406000},"page":"1025","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Concept behind the Suitability of Menstrual Blood-Derived Stem Cells for the Management of Vaginal Atrophy among BRCA Mutation Carriers after RRSO"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-1936","authenticated-orcid":false,"given":"Mariana Robalo","family":"Cordeiro","sequence":"first","affiliation":[{"name":"Gynecology University Clinic, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Gynecology Department, Hospital University Centre of Coimbra, 3004-561 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-3643","authenticated-orcid":false,"given":"B\u00e1rbara","family":"Laranjeiro","sequence":"additional","affiliation":[{"name":"Gynecology University Clinic, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Gynecology Department, Hospital University Centre of Coimbra, 3004-561 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-2667","authenticated-orcid":false,"given":"Margarida","family":"Figueiredo-Dias","sequence":"additional","affiliation":[{"name":"Gynecology University Clinic, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Gynecology Department, Hospital University Centre of Coimbra, 3004-561 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Eleje, G.U., Eke, A.C., Ezebialu, I.U., Ikechebelu, J.I., Ugwu, E.O., and Okonkwo, O.O. (2018). Risk-Reducing Bilateral Salpingo-Oophorectomy in Women with BRCA1 or BRCA2 Mutations, John Wiley and Sons Ltd.. Cochrane Database of Systematic Reviews.","DOI":"10.1002\/14651858.CD012464.pub2"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/OP.21.00382","article-title":"Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes","volume":"18","author":"Liu","year":"2021","journal-title":"JCO Oncol. Pr."},{"key":"ref_3","first-page":"543","article-title":"BRCACarriers, Prophylactic Salpingo-Oophorectomy and Menopause: Clinical Management Considerations and Recommendations","volume":"8","author":"Finch","year":"2012","journal-title":"Women\u2019s Health"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Loizzi, V., Cicinelli, E., Del Vecchio, V., Arezzo, F., Deromemaj, X., Kardhashi, A., Paradiso, A., Legge, F., Natalicchio, M.I., and Resta, L. (2022). A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients. Acta Biomed., 93.","DOI":"10.1136\/ijgc-2021-IGCS.364"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/13697137.2017.1285879","article-title":"Impact of risk-reducing salpingo-oophorectomy in premenopausal women","volume":"20","author":"Vermeulen","year":"2017","journal-title":"Climacteric"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/1471-0528.17511","article-title":"Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations","volume":"130","author":"Nebgen","year":"2023","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit. Rev. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Loizzi, V., Dellino, M., Cerbone, M., Arezzo, F., Cazzato, G., Damiani, G.R., Pinto, V., Silvestris, E., Kardhashi, A., and Cicinelli, E. (2023). The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010764"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Benini, V., Ruffolo, A.F., Casiraghi, A., Degliuomini, R.S., Frigerio, M., Braga, A., Serati, M., Torella, M., Candiani, M., and Salvatore, S. (2022). New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review. Medicina, 58.","DOI":"10.3390\/medicina58060770"},{"key":"ref_11","first-page":"7420","article-title":"A new treatment of genito-urinary post-menopausal atrophy with autologous micro-fragmented fat tissue: A thirty-six months follow up case series","volume":"24","author":"Casarotti","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"NP55","DOI":"10.1093\/asj\/sjab366","article-title":"Cell-Free Fat Extract Prevents Vaginal Atrophy in an Ovariectomized Model by Promoting Proliferation of Vaginal Keratinocytes and Neovascularization","volume":"42","author":"Kang","year":"2021","journal-title":"Aesthetic Surg. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-018-1105-9","article-title":"The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine","volume":"10","author":"Chen","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gaba, F., Blyuss, O., Tan, A., Munblit, D., Oxley, S., Khan, K., Legood, R., and Manchanda, R. (2023). Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15051625"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Stuursma, A., van der Vegt, B., Jansen, L., Berger, L.P.V., Mourits, M.J.E., and de Bock, G.H. (2023). The Effect of Risk-Reducing Salpingo-Oophorectomy on Breast Cancer Incidence and Histopathological Features in Women with a BRCA1 or BRCA2 Germline Pathogenic Variant. Cancers, 15.","DOI":"10.3390\/cancers15072095"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2021.1590","article-title":"Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1\/2 Pathogenic Variant Carriers","volume":"7","author":"Steenbeek","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3390\/curroncol30020185","article-title":"The Psychosocial Impact of the Decision to Undergo Risk-Reducing Salpingo-Oophorectomy Surgery in BRCA Mutation Carriers and the Role of Physician-Patient Communication","volume":"30","author":"Melo","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejogrb.2021.08.001","article-title":"The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1\/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis","volume":"265","author":"Kershaw","year":"2021","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1055\/s-0042-1756148","article-title":"Efficacy of Hormonal and Nonhormonal Approaches to Vaginal Atrophy and Sexual Dysfunctions in Postmenopausal Women: A Systematic Review","volume":"44","author":"Sarmento","year":"2022","journal-title":"Rev. Bras. de Hematol. e Hemoter."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/13697137.2023.2197588","article-title":"Sequential treatment in vulvovaginal atrophy","volume":"26","author":"Palacios","year":"2023","journal-title":"Climacteric"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/aogs.14353","article-title":"The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: A state-of-the-art review","volume":"101","author":"Mortensen","year":"2022","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6118\/jmm.20034","article-title":"Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements","volume":"27","author":"Shim","year":"2021","journal-title":"J. Menopausal Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","author":"Faubion","year":"2022","journal-title":"Menopause"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1111\/1471-0528.16896","article-title":"Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66","volume":"129","author":"Manchanda","year":"2022","journal-title":"BJOG"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3109\/09513590.2010.487609","article-title":"Gynaecologic challenging issues in the management of BRCA mutation carriers: Oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy","volume":"26","author":"Gadducci","year":"2010","journal-title":"Gynecol. Endocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/13697137.2016.1209396","article-title":"Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation","volume":"19","author":"Guidozzi","year":"2016","journal-title":"Climacteric"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.clbc.2023.08.003","article-title":"Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis","volume":"23","author":"Comini","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/13697137.2015.1107039","article-title":"Vulvar and vaginal atrophy in four European countries: Evidence from the European REVIVE Survey","volume":"19","author":"Nappi","year":"2015","journal-title":"Climacteric"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jsm.12190","article-title":"Vulvar and Vaginal Atrophy in Postmenopausal Women: Findings from the REVIVE (REal Women\u2019s VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey","volume":"10","author":"Kingsberg","year":"2013","journal-title":"J. Sex. Med."},{"key":"ref_33","first-page":"445","article-title":"Perceptions of Dyspareunia in Postmenopausal Women with Vulvar and Vaginal Atrophy: Findings from the Revive Survey","volume":"10","year":"2014","journal-title":"Women\u2019s Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4419-7037-4_11","article-title":"Adult stem cells and their niches","volume":"695","author":"Ferraro","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9451492","DOI":"10.1155\/2016\/9451492","article-title":"Pluripotent Stem Cells: Current Understanding and Future Directions","volume":"2016","author":"Romito","year":"2015","journal-title":"Stem Cells Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103501","DOI":"10.1016\/j.isci.2021.103501","article-title":"iScience Understanding menstrual blood-derived stromal\/stem cells: Definition and properties. Are we rushing into their therapeutic applications?","volume":"24","year":"2021","journal-title":"iScience"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13287-019-1503-7","article-title":"Menstrual blood-derived stem cells: Toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases","volume":"10","author":"Chen","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ijgo.13906","article-title":"A new approach to regenerative medicine in gynecology","volume":"157","author":"Mantovani","year":"2021","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13287-021-02511-6","article-title":"Small extracellular vesicles from menstrual blood-derived mesenchymal stem cells (MenSCs) as a novel therapeutic impetus in regenerative medicine","volume":"12","author":"Chen","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_40","unstructured":"(2023, September 28). Stem Cell Therapies in Obstetrics and Gynaecology: The Female Urogenital Tract and the Fetus as Sources and Targets for Molecular and Regenerative Medicine. Available online: https:\/\/www.rcog.org.uk\/media\/31fkqxtt\/sip_38.pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"847213","DOI":"10.3389\/fsurg.2022.847213","article-title":"Therapeutic Potential of Menstrual Blood-Derived Stem Cell Transplantation for Intrauterine Adhesions","volume":"9","author":"He","year":"2022","journal-title":"Front. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13287-016-0458-1","article-title":"Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice","volume":"8","author":"Wang","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1089\/scd.2013.0371","article-title":"Transplantation of Human Menstrual Blood Stem Cells to Treat Premature Ovarian Failure in Mouse Model","volume":"23","author":"Liu","year":"2014","journal-title":"Stem Cells Dev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Erceg Ivko\u0161i\u0107, I., Fure\u0161, R., \u0106osi\u0107, V., Mikelin, N., Buli\u0107, L., Dobrani\u0107, D., Brlek, P., and Primorac, D. (2023). Unlocking the Potential of Mesenchymal Stem Cells in Gynecology: Where Are We Now?. J. Pers. Med., 13.","DOI":"10.3390\/jpm13081253"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41592-020-01003-4","article-title":"Guide RNAs: It\u2019s good to be choosy","volume":"17","author":"Marx","year":"2020","journal-title":"Nat. Methods Nat. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","article-title":"CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy","volume":"18","author":"Xu","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2147\/IJN.S291956","article-title":"A Comprehensive Review on Factors Influences Biogenesis, Functions, Therapeutic and Clinical Implications of Exosomes","volume":"16","author":"Gurunathan","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1432::AID-CNCR9>3.0.CO;2-M","article-title":"Age-related differences in patients with nonpalpable breast carcinomas","volume":"78","author":"Wazer","year":"1996","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1002\/ctm2.694","article-title":"Single-cell RNA sequencing technologies and applications: A brief overview","volume":"12","author":"Jovic","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"143937","DOI":"10.1016\/j.gene.2019.06.027","article-title":"Effects of adipose and bone marrow-derived mesenchymal stem cells on vaginal atrophy in a rat menopause model","volume":"711","author":"Kasap","year":"2019","journal-title":"Gene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24966\/SRDT-2060\/100017","article-title":"Mesenchymal Stromal Cells and Micro Fragmented Adipose Tissue: New Horizons of Effectiveness of Lipogems","volume":"5","author":"Tremolada","year":"2019","journal-title":"J. Stem Cells Res. Dev. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2561461","DOI":"10.1155\/2016\/2561461","article-title":"The Use of Human Adipose-Derived Stem Cells in the Treatment of Physiological and Pathological Vulvar Dystrophies","volume":"2016","author":"Onesti","year":"2016","journal-title":"Stem Cells Int."},{"key":"ref_53","first-page":"1","article-title":"New Possible Approach in Treatment of Experimental Induced Vaginal Atrophy by Bone Marrow-derived Mesenchymal Stem Cells in Treatment of Induced Vaginal Atrophy in Adult Female Albino Rats (Histological, Immunohistochemical and Biochemical Study)","volume":"10","year":"2019","journal-title":"J. Cytol. Histol."},{"key":"ref_54","unstructured":"Michaellweinfeld, F.B. (2023, September 22). Advances in Experimental Medicine and Biology 951 Biobanking and Cryopreservation of Stem Cells. Available online: http:\/\/www.springer.com\/series\/5584."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hoang, V.T., Nguyen, H.-P., Nguyen, V.N., Hoang, D.M., Nguyen, T.-S.T., and Thanh, L.N. (2022). Adipose-derived mesenchymal stem cell therapy for the management of female sexual dysfunction: Literature reviews and study design of a clinical trial. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.956274"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.stemcr.2017.05.029","article-title":"Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications","volume":"9","author":"Andrews","year":"2017","journal-title":"Stem Cell Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/1025\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:25Z","timestamp":1760103985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/1025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,14]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25021025"],"URL":"https:\/\/doi.org\/10.3390\/ijms25021025","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,14]]}}}